Drugs / GDKM-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05628545 | Nov 2021 → Feb 2023 | hepatocellular carcinoma | Guangdong GD Kongming Biotech LLC | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GDKM-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05628545 ↗ |
| Modality | Cell therapy | “GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.” NCT05628545 ↗ |